Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I

Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by stock analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued on Monday, Zacks.com reports.

Several other research firms have also recently weighed in on MRNS. LADENBURG THALM/SH SH cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Truist Financial restated a “buy” rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. JMP Securities reaffirmed a “market outperform” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, September 24th. Finally, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $8.83.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $1.67 on Monday. The firm’s 50 day moving average price is $1.42 and its two-hundred day moving average price is $2.42. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28. Marinus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $11.26. The firm has a market cap of $91.74 million, a P/E ratio of -0.63 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The company had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period in the prior year, the firm posted ($0.61) earnings per share. On average, analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new position in Marinus Pharmaceuticals during the second quarter worth $28,000. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $34,000. AQR Capital Management LLC increased its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $64,000. Finally, Values First Advisors Inc. lifted its stake in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 52,257 shares during the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.